Mirum Surges on Volixibat Success in PSC Itch Trial, FDA Filing Targeted
Markets Daniel Marsh

Mirum Surges on Volixibat Success in PSC Itch Trial, FDA Filing Targeted

Mirum Pharmaceuticals announced volixibat met its primary endpoint in a Phase 2b trial for PSC, reducing itch scores. Shares rose 9%. The company plans a pre-NDA FDA meeting this summer and a U.S. filing in H2 2026.

MIRM GSK
Ouster Shares Surge on Rev8 Lidar Launch Combining Color and Depth Sensing
Technology Sarah Chen

Ouster Shares Surge on Rev8 Lidar Launch Combining Color and Depth Sensing

Ouster stock jumped 7.9% to $28.55 after the launch of Rev8 lidar, which integrates color and depth sensing. Google and Volvo Autonomous Solutions plan to adopt the sensor. Q1 results are expected Tuesday.

OUST
Sangamo Surges Ahead of Nasdaq Exit; OTCQB Switch Set for May 5
Markets Daniel Marsh

Sangamo Surges Ahead of Nasdaq Exit; OTCQB Switch Set for May 5

Sangamo Therapeutics shares surged roughly 33% on Monday as the company prepares to move from Nasdaq to the OTCQB Venture Market on May 5 following a delisting notice.

SGMO
Above Food Ingredients Shares Surge 22% Amid Delayed Filing
Markets Daniel Marsh

Above Food Ingredients Shares Surge 22% Amid Delayed Filing

Above Food Ingredients shares soared 22% to $0.65 in heavy trading Monday, as the company's fiscal 2025 annual report remains delayed due to ongoing audit issues.

ABVE
Cenovus Energy Gains Pre-Earnings as MEG Integration Takes Spotlight
Earnings James Calloway

Cenovus Energy Gains Pre-Earnings as MEG Integration Takes Spotlight

Cenovus Energy shares rose 2.9% to C$40.96 ahead of Q1 results, as CIBC reaffirmed an outperform rating and a C$46 target, highlighting the first full quarter with MEG Energy assets.

CVE
Celcuity Surges 16% on Promising Breast Cancer Drug Data
Markets Daniel Marsh

Celcuity Surges 16% on Promising Breast Cancer Drug Data

Celcuity shares jumped 16% after its lead drug candidate, gedatolisib, met the primary endpoint in a Phase 3 breast cancer trial for PIK3CA-mutant tumors, setting the stage for a supplemental FDA filing.

CELC
DoorDash Enables SNAP Payments for Kroger Delivery Across 2,700 Stores
Technology Sarah Chen

DoorDash Enables SNAP Payments for Kroger Delivery Across 2,700 Stores

DoorDash has begun accepting SNAP/EBT payments for grocery delivery from nearly 2,700 Kroger-family stores, expanding low-income food access and intensifying competition with Uber Eats and Instacart.

DASH KR
MNDR Surges After $119M Hector Capital Pact for BIMA, M&M Helix Buys
Markets Daniel Marsh

MNDR Surges After $119M Hector Capital Pact for BIMA, M&M Helix Buys

Mobile-health Network Solutions shares surged about 60% following a non-binding $119 million framework with Hector Capital to fund acquisitions of BIMA and M&M Helix.

MNDR
SEALSQ Shares Surge on Heavy Options Activity Ahead of Shareholder Vote
Technology Sarah Chen

SEALSQ Shares Surge on Heavy Options Activity Ahead of Shareholder Vote

SEALSQ Corp shares climbed 5% to $3.015 on heavy call option volume ahead of its May 7 shareholder meeting. Preliminary Q1 revenue tripled to $4.1 million.

XLK
Skycorp Solar Surges on $20.2M Deal, Dilution Risks Loom
Markets Daniel Marsh

Skycorp Solar Surges on $20.2M Deal, Dilution Risks Loom

Skycorp Solar shares surged 88.8% after announcing a $20.2M stock-funded acquisition of Nanjing Cesun Power and a $3M private placement, raising dilution concerns.

SEDG TIGO SHLS
Sivers Semiconductors Surges 47% on Nasdaq Dual-Listing Progress and AI Photonics Bet
Technology Sarah Chen

Sivers Semiconductors Surges 47% on Nasdaq Dual-Listing Progress and AI Photonics Bet

Sivers Semiconductors shares surged 47% to SEK 55.95, extending 2024 gains past 1,200%, as the company progresses toward a Nasdaq New York dual listing and a SEK 125 million share issue.

NVDA LITE LUMN V
Destiny Tech100 Soars on AI and SpaceX Hype
Markets Daniel Marsh

Destiny Tech100 Soars on AI and SpaceX Hype

Destiny Tech100 shares jumped 13.4% Monday, driven by demand for its private tech holdings like SpaceX and AI firms. The fund trades at nearly double its NAV.